跳至主要内容
临床试验/NCT01699581
NCT01699581终止2 期

Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

Greg Monohan2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
2 期
状态
终止
发起方
入组人数
35
试验地点
2
主要终点
Hospital length of stay

研究概览

简要总结

Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
  • Any prior diet or supplement will be allowed.
  • Age >18 years.
  • Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.

结局指标

主要结局

Hospital length of stay

时间窗: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge

Days to engraftment

时间窗: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge

次要结局

未报告次要终点

研究者

发起方
Greg Monohan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Greg Monohan

Principal Investigator

University of Kentucky

研究点 (2)

Loading locations...

相似试验

Assessment of Impact Nutritional Program During... | 临床试验